Skip to main content

Table 4 Selected mutations on Candida albicans ERG11 and their features

From: Structural basis for heterogeneous phenotype of ERG11 dependent Azole resistance in C.albicans clinical isolates

Sl.no Mutant Substitution type References Comment Functional nature substituted residues
Active site residues Vital residues
1 ERG11_A114S _Y257H Double mutant Xu et al. 2008; Ge et al. 2010; Ying et al. 2013 Detected in clinical isolates. Described in Azole resistant as well as susceptible isolates. Also described as single mutations (A114S/Y257H) and with various combinations. None None
2 ERG11_D116E Single mutant Chau et al. 2004; Favre et al. 1999; Marichal et al. 1999; Perea et al. 2001; Sanglard et al. 1998a, 1998b; White et al. 2002 Detected in clinical isolates. Described in Azole-susceptible and Azole-resistant isolates. Also in combination with other mutations. D116 None
3 ERG11_D116E_K128T_Y132H_G465S Quadruplet mutant Ying et al. 2013 Detected in clinical isolates. Detected in Azole resistant strains. Several mutations detected as single mutants. D116 Y132
4 ERG11_Y118A Single mutant Chen et al. 2007; Lamb et al. 1997. The mutation have been clearly associated with resistance by experimental methods but have not yet been detected in clinical isolates _ Y118
5 ERG11_Y132H_G450E Double mutant Chau et al. 2004; Favre et al. 1999; Goldman et al. 2004; Loffler et al. 1997, Perea et al. 2001 Detected in clinical isolates. Detected only in Azole resistant strains. _ Y132
6 ERG11_P230L Single mutant Li et al. 2004; Xiao et al. 2004 Detected in clinical isolates. Detected only in Azole resistant strains with increased resistance. _ P230
7 ERG_F380L Single mutant Sanglard and Bille, 2002 Detected in clinical isolates. Associated with Azole resistance. _ F380
8 ERG11_K342R Single mutant Goldman et al. 2004, Ying et al. 2013 Detected in clinical isolates. Described only in Azole-susceptible isolate. None None
  1. Mutants from N terminal end of ERG11.